Digital Breast Tomosynthesis Equipment Market Size to Exceed USD 8,579.6 Mn by 2032

The Digital Breast Tomosynthesis Equipment Market, estimated at USD 3,186.4 Mn in 2025, is expected to exhibit a CAGR of 15.2% and reach USD 8,579.6 Mn by 2032.

The industry is witnessing significant growth driven by rising demand for advanced, reliable, and cost-effective medical devices across diagnostic, therapeutic, and monitoring applications. Rapid advancements in device design, digital health integration, and adoption of minimally invasive technologies are reshaping the competitive landscape. Furthermore, supportive regulatory frameworks, increasing healthcare investments, and the growing focus on patient-centric care are expected to create new growth avenues for market players.

The increasing prevalence of breast cancer across the world is expected to provide lucrative growth opportunities for players. Thus, key market players are focused on adopting growth strategies such as collaboration, which will drive the global digital breast tomosynthesis equipment market. For example, in January 2025, Planmed OY, a designer and manufacturer of imaging systems and accessories for mammography as well as for orthopedic imaging, and IBEX Innovations Ltd., a technology company focused on developing and commercializing a range of advanced X-ray solutions for the medical and security imaging markets, announced that they had signed an agreement to deploy the state-of-the-art IBEX Trueview gridless scatter correction software in the Planmed Clarity product family.

Global Digital Breast Tomosynthesis Equipment Market– Impact of Coronavirus (COVID-19) Pandemic

The World Health Organization (WHO) designated the illness caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), which first appeared in Wuhan (province of Hubei, China) in the last months of 2025 as "coronavirus disease 2025" or COVID-19. This virus spread quickly and had a serious negative impact on the economies, social behaviors, and healthcare of every country in the world.

COVID-19 affected the economy in three main ways:  by directly affecting production and demand, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to the lockdown, several countries such as India, China, Brazil, and others faced problems with regard to the transportation of drugs from one place to another. The reduced number of screening procedures due to the pandemic and the postponement of elective surgeries have affected the demand for digital breast tomosynthesis equipment.

COVID-19 had a negative impact on the global digital breast tomosynthesis equipment market. However, as the situation is gradually stabilizing, the market is expected to recover in the coming years, driven by the rising demand for advanced diagnostic tools for breast cancer screening and diagnosis. For instance, according to an article published in journal of radiology in May 2025, fewer cancers (1650 in 2025 vs. 2171 in 2025) were detected from March to September 2025 as compared with this same period in 2025. These differences were attributable predominantly to a decrease in the number of screen-detected cancers rather than symptomatic cancers.  Specifically,  there  was  a  significant  38%  drop  in  cumulative screen-detected cancers identified in 2025 (722 cancers) compared with the 1169 screen-detected cancers found  in  2025.

Global Digital Breast Tomosynthesis Equipment Market: Key Developments

In October 2025, Fujifilm Corporation, a multinational conglomerate in medical electronics, biotechnology, and chemicals, announced that the company had received Health Canada medical device license for its ASPIRE Cristalle digital mammography solution, and announced its expansion of the partnership with Christie Innomed, a developer, integrator, and distributor of Medical imaging to offer the product with superior service in every province across the Canada. ASPIRE Cristalle is featured with Digital Breast Tomosynthesis (DBT) technology, also known as 3D mammography. DBT is an advanced form of breast imaging that uses a low dose x-ray system to create three-dimensional images of the breasts, which can help radiologists better visualize lesions that can be obscured between varying layers of breast tissue.

In October 2025, The American College of Radiology (ACR), a professional medical society had launched the Contrast-Enhanced Mammography Imaging Screening Trial (CMIST) in collaboration with the Breast Cancer Research Foundation (BCRF) and GE Healthcare. The trial had determine the contrast-enhanced mammography with improved breast cancer detection and reduces false-positive exams in women with dense breasts.

In August 2025, Brigham Health Care Center, had offered new, state-of-the-art mammography services at its location at 15 Corporate Park Drive. This quality care advancement is another example of its commitment to bringing enhanced access to specialty services in the community. The new mammography location features the newest advances in breast imaging and digital 3D mammography, also known as digital breast tomosynthesis, which uses a low-dose X-ray system and computer reconstructions to create 3D images of the breasts.

Browse 29 Market Data Tables and 24 Figures spread through 95 Pages and in-depth TOC on “Global Digital Breast Tomosynthesis Equipment Market”- Forecast to 2032, Global Digital Breast Tomosynthesis Equipment Market, by Product Type (Equipment, and Upgradation) By End User (Hospitals, and Diagnostic Centers), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa).

To know the latest trends and insights prevalent in this market, click the link below:

https://www.coherentmarketinsights.com/market-insight/digital-breast-tomosynthesis-equipment-market-3445

Key Takeaways of the Global Digital Breast Tomosynthesis Equipment Market:

• The global digital breast tomosynthesis equipment market is expected to exhibit a CAGR of 15.2% during the forecast period. The merger with emerging economies offers lucrative growth opportunities for players in the global digital breast tomosynthesis equipment market. The increasing prevalence of breast cancer across the world is the key factor to drive the growth of digital breast tomosynthesis equipment market. In addition, advancements in digital breast tomosynthesis technology have resulted in improved imaging quality and reduced radiation exposure for patients, which has further fueled the growth of the market.
• Among End User, the hospital segment is expected to grow in the global digital breast tomosynthesis equipment market over the forecast period. For instance, according to an article published in the journal of Radiological Society of North America (RSNA) on April 11 2025, the researchers strongly emphasized digital breast tomosynthesis (DBT) had improved breast cancer screening performance in community practice and identifies more invasive cancers, compared to digital mammography. Breast cancer mortality reduction from routine screening is contingent upon radiologists' interpretive performance with DBT equipment.
• Among region, North America is expected to be the dominant region in the global digital breast tomosynthesis equipment market, owing to the increasing launch of products. For instance, in October 2025, Hologic, Inc., a medical technology company announced the commercial availability of its 3DQuorum Imaging Technology, powered by genius AI. The innovation was designed to help improve mammography efficiency and workflow, which is critical as clinics strive to manage the backlog of women whose routine breast screening was delayed due to the COVID-19 lockdown.
• Major players operating in the global digital breast tomosynthesis equipment market include Hologic, Inc., Internazionale Medico Scientifica-S.R.L, GE Healthcare, Siemens Healthineers, Fujifilm Corporation, Planmed OY, Trivitron Healthcare, Varex Imaging Corporation, and Analogic Corporation.